Randomized trials comparing Telmisartan vs. Valsartan and Losartan 24-hour ambulatory blood pressure control, GLP-1 heart failure outcomes, UKPDS 34 cardiovascular mortality reductions, and statin + ezetimibe ApoB targets. Explore 714 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Intramuscular administration of testosterone esters to hypogonadal men is associated with a small, dosage-dependent decrease in HDL cholesterol and concomitant declines in total cholesterol and LDL cholesterol.
The diabetic cohort in ALLHAT wil be able to provide valuable information about the treatment of high blood pressure in older diabetic patients at risk for incident CVD.
The present study documents that with similar control of BP, losartan and amlodipine have opposite effects on kidney hemodynamics and on TGF-beta1 concentrations.
Findings suggest that sildenafil may partially reverse the sexual dysfunction commonly associated with SCI in women.
Severity of sleep-disordered breathing and well-being during the day were not significantly influenced by any of the study compounds.
The study thus shows that high systemic levels of telmisartan, which are well tolerated, can be attained in healthy adults of any age and in hypertensive subjects.
In hypertensive postmenopausal women, daily CEE together with cyclical MPA has a variable effect on blood pressure depending on CEE dose.
Differences in QT dispersion (a predictor for sudden death) were observed in a subgroup of patients in the ELITE heart failure study of losartan compared with captopril, and may explain improved survival with losartan.
There were no significant changes in mean values of fibrinogen between the three groups.
In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves...
D-Chiro-inositol increases the action of insulin in patients with the polycystic ovary syndrome, thereby improving ovulatory function and decreasing serum androgen concentrations, blood pressure, and plasma triglyceride...
Both treatment regimens were well tolerated.
This cost increase translated into a cost-effectiveness ratio of USD 4,047 per year of life gained for losartan relative to captopril.
Our results demonstrate that losartan, but not amlodipine, decreased albumin excretion in hypertensive patients with non-diabetic.
Terminal plasma half-life of EXP3174 after oral administration of losartan was 7.6 hours.
A unique feature of VALUE is the assessment of the predictive power of this heart and blood vessel risk factor scale in a large population of treated hypertensive patients.
Both losartan and amlodipine were effective in lowering the blood pressure and were tolerated well.
We conclude that oral estrogen/progesterone replacement therapy may result in coagulation activation and increased fibrinolytic potential, whereas opposed transdermal estrogen appears without any substantial effects on hemostasis.
This study showed that oral losartan administered to patients with symptomatic heart failure resulted in beneficial blood flow and heart rate effects with short-term administration, with additional beneficial blood flow and...
Patients receiving amlodipine had significantly lower blood pressure compared with placebo 24 hours after the last dose (supine blood pressure -25.1/-10.1 mm Hg; standing blood pressure -21.2/-9.7 mm Hg) after 4 weeks of...
Blockade of the angiotensin II receptor with the antagonist losartan causes vasodilator and neurohormonal effects in patients with congestive heart failure.
Preliminary animal and in vitro investigations have shown that losartan produces beneficial effects on cardiac function, kidney function, and survival that are similar to those of ACE inhibitors.
Treatment order was unrelated to the change in blood pressure values.
High-density-lipoprotein cholesterol and triglyceride levels were also lowered by NET (P less than 0.001-0.02) and there was a slight decrease in phospholipids.
The marked decrease in SHBG and cholesterol levels during oral testosterone undecanoate, when compared with parenteral treatments, occurred despite lesser androgenic effects (suppression of gonadotrophin levels and reported...
However, in that based on the oldest subjects, the results were not statistically significant.
Chronic increases in plasma cholesterol levels, increases in low-density lipoprotein cholesterol levels, and decreases in high-density lipoprotein cholesterol levels may predispose subjects to premature atherosclerosis.
A marked, drug-induced decrease in sebum production was accompanied by a decrease in the concentration of wax esters, a slight decrease in the squalene concentration and in increase in the cholesterol concentration in the skin...
Dapagliflozin improved micro- and macrovascular endothelial function compared to glibenclamide, regardless of blood sugar control in patients with T2DM and subclinical carotid atherosclerotic disease.
In patients with type 2 diabetes and preserved kidney function treatment with M+I resulted in reduction of kidney perfusion and increase in vascular resistance, in contrast to treatment with E+I that preserved kidney perfusion...
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
